A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3

• Ellen Weisberg,
• Martin Sattler

Affiliations

Ellen Weisberg

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Martin Sattler

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA